Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

ABSTRACT: Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL). Therapeutic virtual reality (VR) has emerged as a promising and evidence-based treatment modality for cancer pain. Users of VR wear a pair of goggles with a close-proximity screen in front of the eyes that creates a sensation of being transported into lifelike, three-dimensional worlds. To date, VR has been limited to short-term clinical trials for cancer pain. Moreover, limited research exists on theory-based VR modalities beyond mere distraction, such as VR that employs acceptance and commitment therapy (ACT) with components of biofeedback and mindfulness. To bridge these gaps, this study seeks to: (1) assess the impact of immersive VR on patient-reported outcomes (PROs), including pain, activity metrics, and opioid use among patients with visceral pain from a digestive tract malignancy; (2) assess differences in PROs, activity metrics, and opioid use between skills-based VR therapy vs. distraction VR therapy; and (3) determine patient-level predictors of VR treatment response in visceral cancer pain. To address these aims, the study will measure PROs and opioid use in 360 patients randomized among 3 groups and follow them for 60 days after enrollment: (1) an enhanced VR group receiving skills-based VR; (2) a distraction-based VR group receiving patient-selected VR videos; and (3) a VR sham control group using a VR headset with 2-D content. The results will inform best practices for the implementation of VR for visceral cancer pain management and guide selection of patient-tailored experiences.

DISEASE(S): Esophagus Cancer, Stage Iv,Bile Duct Cancer Stage Ii,Ampullary Cancer,Cancer Pain,Neoplasms,Gastrointestinal Cancers - Small Intestine,Esophagus Cancer,Pancreas Cancer,Esophageal Neoplasms,Bile Duct Cancer Stage I,Colon Cancer,Bile Duct Cancer Stage Iv,Gastrointestinal Cancers - Colorectal,Liver Cancer Stage Iiia,Carcinoid Tumor Of Ileum,Liver Cancer Stage Iiib,Bile Duct Cancer,Liver Cancer Stage Iiic,Anal Cancer Metastatic,Neuroendocrine Tumor,Stomach Neoplasms,Esophagus Cancer, Recurrent,Pancreas Cancer, Stage Iv,Stomach Cancer Recurrent,Carcinoid Tumor,Bile Duct Cancer Stage Ivb,Bile Duct Cancer Stage Iva,Carcinoid Tumor Of Pancreas,Anal Cancer Recurrent,Bile Duct Cancer Recurrent,Peritoneum Cancer,Cancer Of Gastrointestinal Tract,Carcinoid Tumor Of Gi System,Bile Duct Cancer Stage Iii,Rectum Cancer,Rectal Neoplasms,Colon Cancer Stage Iii,Carcinoid Tumor Of The Stomach,Anal Cancer,Small Intestine Cancer, Recurrent,Intestinal Neoplasms,Anal Cancer Stage Iii,Neuroendocrine Tumors,Stomach Cancer,Visceral Pain,Gastrointestinal Neoplasms,Gastrointestinal Cancers - Liver,Biliary Tract Neoplasms,Anal Cancer Stage Iv,Large Intestine Cancer,Liver Cancer,Esophagus Cancer, Stage Iii,Gastrointestinal Cancer Metastatic,Liver Neoplasms,Gallbladder Cancer Stage I,Appendiceal Neoplasms,Esophagus Cancer, Stage I,Gastrointestinal Cancers - Anus,Carcinoid Tumor Of The Small Bowel,Appendix Cancer,Carcinoid Tumor Of Cecum,Colon Cancer Stage Iv,Colorectal Neoplasms,Pancreatic Neoplasms,Cholangiocarcinoma,Digestive System Neoplasms,Gastrointestinal Cancers - Stomach,Small Intestine Cancer Stage Iv,Small Intestine Cancer Stage Iii,Carcinoid Tumor Of Liver,Stomach Cancer Stage Iii,Pancreas Cancer, Stage Iii,Small Intestine Cancer,Gallbladder Cancer,Rectal Cancer,Gallbladder Cancer Stage Iv,Anus Neoplasms,Stomach Cancer Stage Iv,Gastric (stomach) Cancer,Peritoneal Cancer,Anal Cancer, Stage Iiib,Gallbladder Cancer Stage Iii,Pancreas Cancer, Recurrent,Carcinoid Tumor Of Colon,Anal Cancer, Stage Iiia,Biliary Tract Cancer,Pancreas Cancer, Metastatic,Gallbladder Neoplasms,Bile Duct Neoplasms,Gallbladder Cancer Stage Ii,Rectum Cancer, Recurrent,Liver Cancer Stage Iv,Carcinoid Tumor Of Rectum,Carcinoid Tumor Of Large Intestine,Esophagus Cancer, Stage Ii,Colonic Neoplasms

PROVIDER: 2379130 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR